Navigation Links
In Q1 Public Biopharmas Shift Fundraising into Overdrive
Date:4/8/2013

ATLANTA, April 8, 2013 /PRNewswire-USNewswire/ -- Biotech companies generated $5 billion in the first quarter of 2013, just 3% less than the $5.15 billion raised in the first quarter last year. The heavy lifting for the period was carried out by public companies, which were responsible for 65% of the total, according to BioWorld Today, the daily biopharmaceutical news source.

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO )

The $3.25 billion raised by these public companies was 33% higher than the $2.5 billion total raised in the same period of 2012. The amount included almost $3 billion in follow-on financings with public companies seizing the opportunity in a favorable investor climate to sell shares at or near their prevailing market value with little to no price discount.

It has been a great quarter for public biotech companies as the sector continued to remain hot with investors, according to Peter Winter , editor of BioWorld Insight, the analytical companion to BioWorld Today. Large biotech companies, with market caps greater than $1 billion, collectively saw their share prices jump by an average of 21.5% in the first quarter.

That performance almost doubled the Dow Jones Industrial average, which hit a new historical high and closed the quarter up 11.25%.

"A steady flow of positive news from elite biotech companies, including product approvals and strong financial reports, have kept investors engaged. The sector's momentum, which started early last year, shows no signs of slowing down," said Winter.

There is already some evidence that this is starting to happen with the Nasdaq Biotechnology Index (NBI), which includes a broad range of large and smaller companies, jumping 16% in the first quarter. The performance of NBI was also mirrored by the BioWorld Stock Report, which recorded an average share price change for the 231 public biotechnology companies tracked by the report at 15.6%.

Editor's note: This is an excerpt from today's top BioWorld story. Read the complete article here: https://www.bioworld.com/

BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry's most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives. Call for details (800) 477-6307.

Contact: Lynn Yoffee
404-262-5408
www.bioworld.com


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos Files Registration Statement for Proposed Initial Public Offering
2. BioMed Realty Trust Prices Public Offering Of 15,000,000 Shares Of Common Stock
3. Bausch + Lomb Files Registration Statement For Proposed Initial Public Offering
4. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Cardica Prices Public Offering Of Common Stock
6. Cardica Announces Proposed Public Offering of Common Stock
7. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
8. HeartWare International, Inc. Announces Public Offering of Common Stock
9. Chimerix Files Registration Statement for Proposed Initial Public Offering
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology:
(Date:4/26/2017)... Plano, TX (PRWEB) , ... April 26, 2017 ... ... to confer the distinction of Customer Excellence upon National Registry of Emergency ... , “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced ... farmers produce more and better food, with fewer resources. It highlights the business’ ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
Breaking Medicine News(10 mins):